Key Figures Q1 2022

SEK m, unless otherwise stated

2022

Jan-Mar

2021

Jan-Mar

% Change

2021

Jan-Dec

Net revenues

159.4

132.3

20.5%

565.0

Cost of goods sold

-27.5

-19.2

43.8%

-78.9

Operating expenses

-145.1

-149.9

-3.2%

-700.2

EBIT

-13.2

-36.8

64.2%

-214.1

EBIT margin, %

-8.3%

-27.8%

19.6%

-37.9%

EBITDA

2.8

-23,9

111.7%

-161.0

Earnings per share, before dilution, SEK

-0.69

-0.92

25.0%

-6.51

Earnings per share, after dilution, SEK

-0.69

-0.92

25.0%

-6.51

Cash flow from operating activities

-61.6

-47.8

-28.9%

-229.0

Cash and cash equivalents

437.8

725.5

-39.7%

504.1

Net revenues and EBIT per segment Q1 2022

SEK m

Net Revenues

EBIT

 

2022 Jan-Mar

2021  Jan-Mar

2021  Jan-Dec

2022 Jan-Mar

2021  Jan-Mar

2021  Jan-Dec

ZUBSOLV® US

139.1

126.8

522.7

-

-

-

US Pharma – total

139.1

126.8

522.7

84.0

66.1

278.2

Digital Therapeutics (DTx) product sales

0.2

0,2

1.1

-

-

-

Digital Therapeutics (DTx) – total

0.2

0,2

1.1

-43.4

-58.7

-249.7

Abstral® royalties

12.4

2.7

32.1

-

-

-

Edluar® royalties

3.2

2.6

9.1

-

-

-

ZUBSOLV® - ex US

4.6

-

-

-

-

-

HQ & Pipeline segment - total

20.1

5.3

41.2

-53.7

-44.2

-242.6

Total

159.4

132.3

565.0

-13.2

-36.8

-214.1

Cash flow Q1 2022

 

SEK m

2022

Jan-Mar

2021

Jan-Mar

2021

Jan-Dec

Cash flow from operating activities

-61.6

-47.8

-299.0

Investment activities

-5.6

-16.2

-52.9

Financing activities

-5.3

261.7

250.6

Cash flow (excl exchange rate differences)

-72.5

197.7

-31,2

Liquid funds

437.8

725.5

504.1